Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/26/22	HK$20.88	+4.56%	90,300
21/26/21	HK$19.97	-3.15%	91,600
18/26/18	HK$20.62	+6.51%	1,49,300
17/26/17	HK$19.36	+0.94%	81,600
16/26/16	HK$19.18	+1.32%	1,65,400

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

17.82CNY

Average target price

19.66CNY

Spread / Average Target

+10.34%

Consensus

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 01:38:13 22/09/2026 pm IST			5-day change	1st Jan Change
20.88 ^HKD	+4.56%		+10.71%	-31.50%

27/08	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
31/07	Medtide Names CFO	MT

Market Cap	252.72Cr 295.85Cr 38Cr 33Cr 31Cr 28Cr 53Cr 3.61TCr 53Cr 371.81Cr 143.47Cr 1.84TCr 141.65Cr 138.54Cr 5.94TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	194.82Cr 228.08Cr 29Cr 25Cr 24Cr 22Cr 41Cr 2.78TCr 41Cr 286.64Cr 110.61Cr 1.42TCr 109.2Cr 106.8Cr 4.58TCr	EV / Sales 2026 *	3.25x	EV / Sales 2027 *	2.53x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

27/08	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
31/07	Medtide Names CFO	MT
31/07	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
31/07	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
31/07	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
31/07	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
30/06	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
18/06	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
31/03	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/03	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
26/02	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
26/02	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
06/02	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	+4.56%
1 week	+10.71%
Current month	-5.86%
1 month	-10.54%
3 months	-7.28%
6 months	-4.22%
Current year	-31.50%

1 week	18.42	21.3
1 month	17.64	23.6
Current year	17.64	30.46
1 year	17.64	33.18
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	31/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03/26	Qi Xu	Other	Chief Executive Officer	6,82,01,112	48.0967%
09/03/26	Xiang Li Li	Other	Director	6,82,01,112	48.0967%
09/03/26	Qi Xu	Other	Chief Executive Officer	6,82,01,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+4.56%	+10.71%	-31.76%	-	36Cr
LONZA GROUP AG	+2.55%	+4.77%	+4.07%	+32.02%	4.67TCr
IQVIA HOLDINGS INC.	+0.50%	+0.65%	+44.51%	+36.57%	4.44TCr
REVOLUTION MEDICINES, INC.	+0.49%	-5.43%	+336.25%	+545.80%	4.13TCr
BEONE MEDICINES AG	-0.58%	+4.76%	+7.45%	+90.47%	4.16TCr
CELLTRION, INC.	-1.60%	-0.17%	+9.73%	+43.63%	3.01TCr
MEDPACE HOLDINGS, INC.	+1.01%	+1.65%	+26.63%	+159.90%	1.74TCr
ASCENDIS PHARMA A/S	-1.07%	-2.03%	-	-	1.56TCr
EUROFINS SCIENTIFIC SE	+1.15%	+7.46%	+25.97%	+43.93%	1.55TCr
TEMPUS AI, INC.	-2.22%	+12.29%	-9.97%	-	1.41TCr
Average	+0.57%	+3.64%	+45.88%	+136.04%	2.67TCr
Weighted average by Cap.	+0.36%	+1.95%	+69.09%	+144.30%

	2026 *	2027 *
Net sales	60Cr 70Cr 8.93Cr 7.81Cr 7.34Cr 6.7Cr 13Cr 854.07Cr 13Cr 88Cr 34Cr 436.16Cr 34Cr 33Cr 1.41TCr	74Cr 87Cr 11Cr 9.68Cr 9.1Cr 8.3Cr 16Cr 1.06TCr 16Cr 109.2Cr 42Cr 540.83Cr 42Cr 41Cr 1.74TCr
Net income	-	-
Net Debt	-58Cr -68Cr -8.64Cr -7.55Cr -7.1Cr -6.48Cr -12Cr -826.04Cr -12Cr -85Cr -33Cr -421.84Cr -32Cr -32Cr -1.36TCr	-65Cr -76Cr -9.69Cr -8.46Cr -7.96Cr -7.26Cr -14Cr -925.97Cr -14Cr -95Cr -37Cr -472.87Cr -36Cr -36Cr -1.52TCr